WELCOME TO The Biotechnology REPORT
Altor Bioscience Corporation
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
BeiGene | November 23, 2021
BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists.
TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...
Viva Biotech, BioMap | May 11, 2021
The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology.
Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...
BOSTON LABS | September 23, 2021
Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services.
The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network ...
European Biotechnology | February 17, 2020
PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). The PDUFA date was set for August 16, 2020 by the US Food and Drug Administration (FDA) for lurbinectedin as second-line treatment for patients with SCLC who relapsed following platium-based chemotherapy. The synthetic drug developed by PharmaMar SA (Madrid, Spain) and exclusively licenced by Jazz Pharmaceuticals plc (Dublin, Ireland) in December 2019 works b...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE